Generics companies to move away from "little white pills"14 Oct 2018
Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.
In an increasingly competitive market, it is widely accepted that generics companies are facing enormous downward pricing pressure. The mix of new product opportunities is changing, innovators are devising stronger defensive strategies, and the regulatory burden is becoming more expensive.
Drawing from his recent White Paper, "Generics companies, responding to tough times, steer towards higher-risk portfolio strategies", Brandon Boyd of Clarivate Analytics outlined the various portfolio strategies open to generics companies and their uptake to a packed audience at CPhI Worldwide in Madrid. Common to all was a willingness to accept higher levels of risk.
First, serving new channels such as hospitals and even government programs leads to demands on a whole range of factors from packaging through to final documentation. Second, enhancing entry strategies with patent challenges offers the extremely high risk/reward option compared with waiting for patent expiry. Third, moving up the product value chain from oral solids ("little white pills") to injectables and drug-device combinations, while appealing, often requires entering complex partnerships or M&As with all the attached unknowns.
As examples of this he pointed to the case of generic Advair, which still hasn’t been approved despite repeated attempts and generic Copaxone which, while approved with multiple players, still seems a risky area.
So, will generics companies take these risks? The answer according to Boyd appears to be 'yes' – in particular, Indian and Chinese companies are taking some or even all three of the above options. He concluded that meeting the challenge to differentiate will dominate the sector for the foreseeable future and that only those with patience, an unswerving focus on quality and execution will survive.
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
DSCSA one-month countdown!
30 Oct 2018
With only a month to go, it really is too late to start trying to develop an in-house solution.Read more
Global pharma set for strong year
23 Oct 2018
Eight of the top ten pharma nations reporting improving market conditions.Read more
CMOs to benefit from double digit approvals for ADCs in the next 3 years
9 Oct 2018
Therapeutic ADC market expected to reach $4 billion by 2023.Read more
Movement on the market reflected at CPhI Worldwide 2018
3 Oct 2018
Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.Read more
Sanofi to refocus two global business units
19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation